Etzer Darout
Stock Analyst at Barclays
(4.12)
# 490
Out of 5,058 analysts
143
Total ratings
53.04%
Success rate
12.02%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Etzer Darout
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRRK Scholar Rock Holding | Maintains: Overweight | $44 → $45 | $38.79 | +16.01% | 7 | Nov 17, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Overweight | $27 → $28 | $26.65 | +5.07% | 9 | Nov 11, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Underweight | $25 → $21 | $24.85 | -15.49% | 2 | Nov 11, 2025 | |
| ANAB AnaptysBio | Maintains: Overweight | $83 → $70 | $36.15 | +93.64% | 2 | Nov 11, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $58 → $56 | $28.01 | +99.93% | 3 | Nov 7, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $72 → $88 | $86.24 | +2.04% | 4 | Nov 7, 2025 | |
| JANX Janux Therapeutics | Maintains: Overweight | $47 → $48 | $28.96 | +65.75% | 2 | Nov 7, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $15 → $16 | $11.40 | +40.41% | 6 | Nov 6, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $60 → $70 | $65.01 | +7.68% | 3 | Nov 5, 2025 | |
| EXEL Exelixis | Maintains: Equal-Weight | $40 → $41 | $42.08 | -2.57% | 5 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $6 → $23 | $15.98 | +43.93% | 7 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $16 | $16.56 | -3.38% | 2 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3.5 → $6 | $3.62 | +65.75% | 12 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $61 | $3.99 | +1,430.74% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $48 | $27.90 | +72.07% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $83.19 | +50.27% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $16 | $8.92 | +79.37% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $142 | $112.45 | +26.28% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $112 → $97 | $95.91 | +1.14% | 8 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $10 | $2.47 | +305.68% | 5 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $3 | $1.45 | +106.90% | 10 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $13 | $4.16 | +212.88% | 4 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 → $143 | $101.69 | +40.62% | 4 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $22 → $3 | $2.12 | +41.51% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $14.16 | +147.18% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $1.82 | +3,361.54% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $27 | $2.36 | +1,044.07% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $134 | $107.11 | +25.11% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 → $48 | $30.38 | +58.02% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $118 → $120 | $126.76 | -5.33% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $1.03 | +482.52% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $82 | $88.86 | -7.72% | 4 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $19 | $4.98 | +281.91% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $170 | $459.25 | -62.98% | 2 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $54 | $54.34 | -0.63% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $38 | $70.19 | -45.86% | 2 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $52 | $2.41 | +2,057.68% | 1 | Mar 28, 2018 |
Scholar Rock Holding
Nov 17, 2025
Maintains: Overweight
Price Target: $44 → $45
Current: $38.79
Upside: +16.01%
Terns Pharmaceuticals
Nov 11, 2025
Maintains: Overweight
Price Target: $27 → $28
Current: $26.65
Upside: +5.07%
Celldex Therapeutics
Nov 11, 2025
Maintains: Underweight
Price Target: $25 → $21
Current: $24.85
Upside: -15.49%
AnaptysBio
Nov 11, 2025
Maintains: Overweight
Price Target: $83 → $70
Current: $36.15
Upside: +93.64%
RAPT Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $58 → $56
Current: $28.01
Upside: +99.93%
Protagonist Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $72 → $88
Current: $86.24
Upside: +2.04%
Janux Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $47 → $48
Current: $28.96
Upside: +65.75%
Arvinas
Nov 6, 2025
Maintains: Overweight
Price Target: $15 → $16
Current: $11.40
Upside: +40.41%
Kymera Therapeutics
Nov 5, 2025
Maintains: Overweight
Price Target: $60 → $70
Current: $65.01
Upside: +7.68%
Exelixis
Nov 5, 2025
Maintains: Equal-Weight
Price Target: $40 → $41
Current: $42.08
Upside: -2.57%
Oct 29, 2025
Upgrades: Overweight
Price Target: $6 → $23
Current: $15.98
Upside: +43.93%
Oct 21, 2025
Maintains: Underweight
Price Target: $13 → $16
Current: $16.56
Upside: -3.38%
Oct 21, 2025
Maintains: Overweight
Price Target: $3.5 → $6
Current: $3.62
Upside: +65.75%
Oct 13, 2025
Initiates: Overweight
Price Target: $61
Current: $3.99
Upside: +1,430.74%
Oct 13, 2025
Initiates: Overweight
Price Target: $48
Current: $27.90
Upside: +72.07%
Oct 13, 2025
Initiates: Overweight
Price Target: $125
Current: $83.19
Upside: +50.27%
Oct 13, 2025
Initiates: Overweight
Price Target: $16
Current: $8.92
Upside: +79.37%
Oct 13, 2025
Initiates: Overweight
Price Target: $142
Current: $112.45
Upside: +26.28%
Sep 30, 2025
Downgrades: Equal-Weight
Price Target: $112 → $97
Current: $95.91
Upside: +1.14%
Sep 23, 2025
Maintains: Overweight
Price Target: $8 → $10
Current: $2.47
Upside: +305.68%
Sep 17, 2025
Assumes: Overweight
Price Target: $3
Current: $1.45
Upside: +106.90%
Sep 2, 2025
Maintains: Buy
Price Target: $9 → $13
Current: $4.16
Upside: +212.88%
Mar 11, 2025
Maintains: Outperform
Price Target: $130 → $143
Current: $101.69
Upside: +40.62%
Feb 11, 2025
Downgrades: Market Perform
Price Target: $22 → $3
Current: $2.12
Upside: +41.51%
Dec 6, 2024
Initiates: Outperform
Price Target: $35
Current: $14.16
Upside: +147.18%
Dec 6, 2024
Initiates: Outperform
Price Target: $63
Current: $1.82
Upside: +3,361.54%
Nov 14, 2024
Maintains: Outperform
Price Target: $28 → $27
Current: $2.36
Upside: +1,044.07%
Nov 13, 2024
Maintains: Outperform
Price Target: $132 → $134
Current: $107.11
Upside: +25.11%
Nov 8, 2024
Reiterates: Outperform
Price Target: $46 → $48
Current: $30.38
Upside: +58.02%
Oct 30, 2024
Maintains: Market Perform
Price Target: $118 → $120
Current: $126.76
Upside: -5.33%
May 10, 2024
Maintains: Market Perform
Price Target: $7 → $6
Current: $1.03
Upside: +482.52%
Apr 26, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $88.86
Upside: -7.72%
Apr 25, 2023
Maintains: Outperform
Price Target: $20 → $19
Current: $4.98
Upside: +281.91%
Feb 3, 2022
Upgrades: Buy
Price Target: $170
Current: $459.25
Upside: -62.98%
Feb 26, 2021
Initiates: Buy
Price Target: $54
Current: $54.34
Upside: -0.63%
Sep 9, 2020
Maintains: Buy
Price Target: $27 → $38
Current: $70.19
Upside: -45.86%
Mar 28, 2018
Maintains: Outperform
Price Target: $54 → $52
Current: $2.41
Upside: +2,057.68%